AZD4547 and FGFR Amplification in Advanced Solid Tumors

June 16, 2014
Hendrik-Tobias Arkenau, MD, PhD

Hendrik-Tobias Arkenau, MD, PhD, medical director, Sarah Canon Research Institute, discusses an exploratory analysis of a phase I study of AZD4547 in patients with advanced tumors.

Hendrik-Tobias Arkenau, MD, PhD, medical director, Sarah Canon Research Institute, discusses an exploratory analysis of a phase I study of AZD4547 in patients with advanced tumors.

Clinical Pearls:

  • AZD4547, an inhibitor of fibroblast growth factor receptor (FGFR), has demonstrated promise in patients who have FGFR amplification in their tumor.
  • FGFR amplification is rare.
  • Tumor biology is complex, so there may be other alterations that may predict if AZD4547 is working.
  • Of 21 patients dosed with AZD4547, seven had high FGFR and three of these patients (squamous NSCLC, breast and bladder cancer) had target lesion shrinkage or prolonged (≥24 weeks) disease stabilization.
  • Further work is needed to better understand FGFR signaling.

<<<

View more from the 2014 ASCO Annual Meeting